These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18584352)

  • 1. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
    Berretta M; Di Benedetto F; Bearz A; Simonelli C; Martellotta F; Del Ben C; Berretta S; Spina M; Tirelli U
    Cancer Invest; 2008 Jul; 26(6):610-4. PubMed ID: 18584352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
    des Guetz G; Mariani P; Cucherousset J; Benamoun M; Lagorce C; Sastre X; Le Toumelin P; Uzzan B; Perret GY; Morere JF; Breau JL; Fagard R; Schischmanoff PO
    Anticancer Res; 2007; 27(4C):2715-9. PubMed ID: 17695437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
    Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A
    Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
    Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
    Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
    Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
    Sugimoto M; Yasuda H; Koda K; Yamazaki M; Tezuka T; Takenoue T; Kosugi C; Higuchi R; Yamamoto S; Watayo Y; Yagawa Y; Suzuki M
    Hepatogastroenterology; 2007 Sep; 54(78):1684-8. PubMed ID: 18019695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
    Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
    Garrido M; Melgoza G; Galindo H; Madrid J; Sánchez C; Nervi B; Alvarez M; Orellana E
    Rev Med Chil; 2007 Nov; 135(11):1380-7. PubMed ID: 18259648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
    Berretta M; Martellotta F; Simonelli C; Di Benedetto F; De Ruvo N; Drigo A; Bearz A; Spina M; Zanet E; Berretta S; Tirelli U
    J Chemother; 2007 Jun; 19(3):343-6. PubMed ID: 17594933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
    Cao W; Yang W; Lou G; Jiang J; Geng M; Xi W; Li H; Ma T; Jin Y
    Anticancer Drugs; 2009 Apr; 20(4):287-93. PubMed ID: 19177020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
    Sato T; Kokuba Y; Ozawa H; Hatate K; Nakamura T; Onosato W; Ihara A; Watanabe M
    Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():257-9. PubMed ID: 17469353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.